8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 30, 2026·SEC
Akebia Therapeutics, Inc.(AKBA)Earnings, Financials & Key Ratios
AKBA•NASDAQ
$1.48
$393M mkt cap·Price updated May 6, 2026
AboutAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$236M+47.5%
- EBITDA$23M+281.2%
- Net Income-$5M+92.3%
- EPS (Diluted)-0.02+93.9%
- Gross Margin83.29%+37.5%
- EBITDA Margin9.95%+222.9%
- Operating Margin9.95%+131.6%
- Net Margin-2.26%+94.8%
- ROE-16.39%
AKBA Key Insights
Akebia Therapeutics, Inc. (AKBA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 28.8% free cash flow margin
✗Weaknesses
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 21.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 11.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AKBA Price & Volume
Akebia Therapeutics, Inc. (AKBA) stock price & volume — 10-year historical chart
Loading chart...
AKBA Growth Metrics
Akebia Therapeutics, Inc. (AKBA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-4.33%
3 Years-6.88%
TTM47.46%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.85%
Return on Capital
10 Years-43.45%
5 Years-30.65%
3 Years-15.89%
Last Year13.3%
AKBA Recent Earnings
Akebia Therapeutics, Inc. (AKBA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 26, 2026EPS
$0.05
Est $0.03
-66.7%
Revenue
$58M
Est $46M
+25.0%
Q4 2025
Nov 10, 2025EPS
$0.00
Est $0.06
+103.3%
Revenue
$59M
Est $48M
+21.5%
Q3 2025
Aug 7, 2025EPS
$0.00
Est $0.02
+104.6%
Revenue
$62M
Est $48M
+30.5%
Q2 2025
May 8, 2025EPS
$0.03
Est $0.03
+200.0%
Revenue
$57M
Est $51M
+12.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.05vs $0.03-66.7% | $58Mvs $46M+25.0% |
| Q4 2025 | Nov 10, 2025 | $0.00vs $0.06+103.3% | $59Mvs $48M+21.5% |
| Q3 2025 | Aug 7, 2025 | $0.00vs $0.02+104.6% | $62Mvs $48M+30.5% |
| Q2 2025 | May 8, 2025 | $0.03vs $0.03+200.0% | $57Mvs $51M+12.9% |
Based on last 12 quarters of dataView full earnings history →
AKBA Peer Comparison
Akebia Therapeutics, Inc. (AKBA) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 CYCN | 14.03M | 3.24 | -2.97 | 3.7% | -170.11% | -39.23% | ||
 ANIP | 1.78B | 84.06 | 25.32 | 43.78% | 8.87% | 14.49% | 0.60 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 FXNC | 248.63M | 27.50 | 14.03 | 27.11% | 9.98% | 0.23 | ||
 GSK | 101.62B | 50.53 | 6.69 | 4.11% | 19.19% | 31.48% | 1.11 |
Compare AKBA vs Peers
Akebia Therapeutics, Inc. (AKBA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AKBA Income Statement
Akebia Therapeutics, Inc. (AKBA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 177.98M | 207.74M | 335M | 294.64M | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Revenue Growth % | 11495.05% | 16.72% | 61.26% | -12.05% | -28.17% | 38.19% | -33.46% | -17.7% | 47.46% |
| Cost of Goods Sold | 617K | 7.68M | 145.34M | 63.96M | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| COGS % of Revenue | 0.35% | 3.7% | 43.38% | 21.71% | 38.5% | 7.69% | 38.1% | 39.44% | 16.71% |
| Gross Profit | 177.37M▲ 0% | 200.06M▲ 12.8% | 189.66M▼ 5.2% | 230.68M▲ 21.6% | 130.16M▼ 43.6% | 269.99M▲ 107.4% | 120.47M▼ 55.4% | 97M▼ 19.5% | 196.73M▲ 102.8% |
| Gross Margin % | 99.65% | 96.3% | 56.62% | 78.29% | 61.5% | 92.31% | 61.9% | 60.56% | 83.29% |
| Gross Profit Growth % | 255.24% | 12.79% | -5.19% | 21.63% | -43.58% | 107.43% | -55.38% | -19.48% | 102.81% |
| Operating Expenses | 257.9M | 378.2M | 475.95M | 608.51M | 394.66M | 350.77M | 166.73M | 147.47M | 169.84M |
| OpEx % of Revenue | 144.9% | 182.05% | 142.08% | 206.52% | 186.47% | 119.93% | 85.67% | 92.07% | 71.91% |
| Selling, General & Admin | 27.01M | 87.06M | 149.46M | 154.1M | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| SG&A % of Revenue | 15.17% | 41.91% | 44.61% | 52.3% | 82.28% | 47.39% | 51.5% | 66.52% | 45.5% |
| Research & Development | 230.89M | 291.07M | 322.97M | 218.49M | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| R&D % of Revenue | 129.73% | 140.11% | 96.41% | 74.15% | 69.86% | 56.75% | 32.41% | 23.51% | 26.4% |
| Other Operating Expenses | 204K | 0 | 3.53M | 235.92M | 72.67M | 46.18M | 3.42M | 3.28M | 0 |
| Operating Income | -79.92M▲ 0% | -178.14M▼ 122.9% | -286.29M▼ 60.7% | -377.83M▼ 32.0% | -264.5M▲ 30.0% | -80.78M▲ 69.5% | -46.26M▲ 42.7% | -50.47M▼ 9.1% | 23.5M▲ 146.6% |
| Operating Margin % | -44.9% | -85.75% | -85.46% | -128.23% | -124.97% | -27.62% | -23.77% | -31.51% | 9.95% |
| Operating Income Growth % | 41.44% | -122.91% | -60.71% | -31.97% | 29.99% | 69.46% | 42.74% | -9.11% | 146.56% |
| EBITDA | -79.3M | -175.72M | -249.87M | -343.13M | -226.53M | -43.08M | -8.63M | -12.97M | 23.5M |
| EBITDA Margin % | -44.55% | -84.59% | -74.59% | -116.46% | -107.03% | -14.73% | -4.43% | -8.1% | 9.95% |
| EBITDA Growth % | 41.76% | -121.59% | -42.2% | -37.32% | 33.98% | 80.98% | 79.97% | -50.28% | 281.21% |
| D&A (Non-Cash Add-back) | 617K | 2.42M | 36.42M | 34.69M | 37.97M | 37.7M | 37.63M | 37.5M | 0 |
| EBIT | -76.67M | -178.16M | -286.29M | -174.52M | -227.88M | -34.64M | -45.89M | -51.23M | 0 |
| Net Interest Income | 2.8M | 6.15M | 792K | -8.87M | -19.94M | -15.69M | -6.03M | -18.18M | 0 |
| Interest Income | 2.8M | 6.15M | 2.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 1.4M | 8.87M | 19.94M | 15.69M | 6.03M | 18.18M | 0 |
| Other Income/Expense | 3M | 6.24M | -2K | -7.01M | -17.52M | -13.45M | -5.67M | -18.94M | 0 |
| Pretax Income | -76.91M▲ 0% | -171.9M▼ 123.5% | -286.29M▼ 66.5% | -384.84M▼ 34.4% | -282.02M▲ 26.7% | -94.23M▲ 66.6% | -51.92M▲ 44.9% | -69.41M▼ 33.7% | -3.72M▲ 94.6% |
| Pretax Margin % | -43.21% | -82.75% | -85.46% | -130.61% | -133.25% | -32.22% | -26.68% | -43.33% | -1.58% |
| Income Tax | -2.8M | -28.34M | -6.63M | 0 | 0 | 0 | 0 | 0 | -1.62M |
| Effective Tax Rate % | 3.64% | 16.48% | 2.32% | 0% | 0% | 0% | 0% | 0% | 43.64% |
| Net Income | -76.91M▲ 0% | -171.9M▼ 123.5% | -279.66M▼ 62.7% | -384.84M▼ 37.6% | -282.02M▲ 26.7% | -94.23M▲ 66.6% | -51.92M▲ 44.9% | -69.41M▼ 33.7% | -5.34M▲ 92.3% |
| Net Margin % | -43.21% | -82.75% | -83.48% | -130.61% | -133.25% | -32.22% | -26.68% | -43.33% | -2.26% |
| Net Income Growth % | 43.34% | -123.5% | -62.68% | -37.61% | 26.72% | 66.59% | 44.89% | -33.67% | 92.3% |
| Net Income (Continuing) | -73.67M | -143.59M | -279.66M | -384.84M | -282.02M | -94.23M | -51.92M | -69.41M | -5.34M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.77▲ 0% | -1.47▲ 16.9% | -2.36▼ 60.5% | -2.53▼ 7.2% | -1.48▲ 41.5% | -0.58▲ 60.8% | -0.28▲ 51.7% | -0.33▼ 17.9% | -0.02▲ 93.9% |
| EPS Growth % | 50.83% | 16.95% | -60.54% | -7.2% | 41.5% | 60.81% | 51.72% | -17.86% | 93.94% |
| EPS (Basic) | -1.77 | -1.47 | -2.36 | -2.53 | -1.48 | -0.58 | -0.28 | -0.33 | -0.02 |
| Diluted Shares Outstanding | 43.5M | 116.89M | 118.4M | 138.46M | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Basic Shares Outstanding | 43.5M | 116.89M | 118.4M | 138.46M | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AKBA Balance Sheet
Akebia Therapeutics, Inc. (AKBA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 358.36M | 468.27M | 309.53M | 371.44M | 271.15M | 185.18M | 118.15M | 113.83M | 184.84M |
| Cash & Short-Term Investments | 317.79M | 321.64M | 147.96M | 269.08M | 149.8M | 90.47M | 42.92M | 51.87M | 184.84M |
| Cash Only | 70.16M | 104.64M | 147.71M | 229.09M | 149.8M | 90.47M | 42.92M | 51.87M | 184.84M |
| Short-Term Investments | 247.64M | 217M | 245K | 39.99M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 34.22M | 16.67M | 38.86M | 28.57M | 51.58M | 40.28M | 39.29M | 34.37M | 47.03M |
| Days Sales Outstanding | 70.17 | 29.28 | 42.34 | 35.4 | 88.95 | 50.27 | 73.69 | 78.31 | 72.68 |
| Inventory | 0 | 114.25M | 116.35M | 61.02M | 36.63M | 21.57M | 15.69M | 16.24M | 15.61M |
| Days Inventory Outstanding | - | 5.43K | 292.2 | 348.19 | 164.05 | 349.94 | 77.24 | 93.84 | 144.38 |
| Other Current Assets | 6.35M | 15.72M | 6.36M | 12.76M | 0 | 32.86M | 20.24M | 7.32M | -62.64M |
| Total Non-Current Assets | 5.89M | 528.26M | 461.67M | 272.7M | 258.2M | 170.87M | 123.55M | 106.84M | 191.72M |
| Property, Plant & Equipment | 3.62M | 8.02M | 39.42M | 35.5M | 40.61M | 34.37M | 16.05M | 10.42M | 0 |
| Fixed Asset Turnover | 49.21x | 25.89x | 8.50x | 8.30x | 5.21x | 8.51x | 12.13x | 15.38x | - |
| Goodwill | 0 | 55.05M | 55.05M | 55.05M | 59.04M | 59.04M | 59.04M | 59.04M | 59.04M |
| Intangible Assets | 0 | 328.15M | 291.21M | 144.17M | 108.13M | 72.08M | 36.04M | 0 | 0 |
| Long-Term Investments | 1.28M | 2.46M | 2.09M | 2.04M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.27M | 21.8M | 73.89M | 35.94M | 50.42M | 5.37M | 12.42M | 37.38M | 132.68M |
| Total Assets | 364.25M▲ 0% | 996.54M▲ 173.6% | 771.2M▼ 22.6% | 644.14M▼ 16.5% | 529.35M▼ 17.8% | 356.05M▼ 32.7% | 241.7M▼ 32.1% | 220.67M▼ 8.7% | 376.56M▲ 70.6% |
| Asset Turnover | 0.49x | 0.21x | 0.43x | 0.46x | 0.40x | 0.82x | 0.81x | 0.73x | 0.63x |
| Asset Growth % | 21.33% | 173.59% | -22.61% | -16.48% | -17.82% | -32.74% | -32.12% | -8.7% | 70.65% |
| Total Current Liabilities | 144.35M | 265.69M | 208.12M | 187.15M | 261.05M | 129.54M | 99.87M | 80.91M | 162.94M |
| Accounts Payable | 7M | 42.8M | 39.22M | 41.31M | 33.59M | 18.02M | 14.63M | 15.18M | 0 |
| Days Payables Outstanding | 4.14K | 2.03K | 98.49 | 235.72 | 150.44 | 292.39 | 72.04 | 87.7 | - |
| Short-Term Debt | 0 | 15M | 4.99M | 5.29M | 97.54M | 32M | 19.55M | 4.31M | 0 |
| Deferred Revenue (Current) | 84.91M | 56.98M | 70.38M | 53.26M | 20.91M | 3.74M | 0 | 0 | 0 |
| Other Current Liabilities | 46.47M | 26.82M | 80.93M | 72.89M | 31.18M | 52.53M | 18.26M | 22.75M | 162.94M |
| Current Ratio | 2.48x | 1.76x | 1.49x | 1.98x | 1.04x | 1.43x | 1.18x | 1.41x | 1.13x |
| Quick Ratio | 2.48x | 1.33x | 0.93x | 1.66x | 0.90x | 1.26x | 1.03x | 1.21x | 1.04x |
| Cash Conversion Cycle | - | 3.42K | 236.06 | 147.87 | 102.57 | 107.82 | 78.88 | 84.46 | - |
| Total Non-Current Liabilities | 100.57M | 94.92M | 168.33M | 209.38M | 194.29M | 221.29M | 172.42M | 188.94M | 181.02M |
| Long-Term Debt | 0 | 0 | 75.81M | 96.38M | 0 | 34.08M | 71.2M | 175.47M | 0 |
| Capital Lease Obligations | 0 | 0 | 27.53M | 24.62M | 33.7M | 28.96M | 8.95M | 3.55M | 0 |
| Deferred Tax Liabilities | 181K | 6.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.61M | 32.58M | 31.87M | 63.03M | 139.11M | 114.95M | 48.98M | 9.93M | 181.02M |
| Total Liabilities | 244.92M | 360.61M | 376.44M | 396.52M | 455.34M | 350.82M | 272.29M | 269.86M | 343.95M |
| Total Debt | 0 | 15M | 108.32M | 126.28M | 136.05M | 99.78M | 104.18M | 188.73M | 0 |
| Net Debt | -70.16M | -89.64M | -39.39M | -102.81M | -13.75M | 9.32M | 61.26M | 136.86M | -184.84M |
| Debt / Equity | - | 0.02x | 0.27x | 0.51x | 1.84x | 19.08x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -7.87x |
| Interest Coverage | - | - | -204.49x | -42.59x | -13.27x | -5.15x | -7.67x | -2.78x | - |
| Total Equity | 119.33M▲ 0% | 635.93M▲ 432.9% | 394.76M▼ 37.9% | 247.62M▼ 37.3% | 74.01M▼ 70.1% | 5.23M▼ 92.9% | -30.58M▼ 684.8% | -49.19M▼ 60.8% | 32.61M▲ 166.3% |
| Equity Growth % | 75.18% | 432.91% | -37.92% | -37.27% | -70.11% | -92.93% | -684.78% | -60.82% | 166.3% |
| Book Value per Share | 2.74 | 5.44 | 3.33 | 1.79 | 0.45 | 0.03 | -0.16 | -0.23 | 0.13 |
| Total Shareholders' Equity | 119.33M | 635.93M | 394.76M | 247.62M | 74.01M | 5.23M | -30.58M | -49.19M | 32.61M |
| Common Stock | 0 | 1K | 1K | 1K | 1K | 2K | 2K | 2K | 2K |
| Retained Earnings | -374.05M | -514.39M | -794.05M | -1.18B | -1.46B | -1.56B | -1.61B | -1.68B | -1.68B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -442K | -261K | 0 | 13K | 6K | 6K | 6K | 6K | 6K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AKBA Cash Flow Statement
Akebia Therapeutics, Inc. (AKBA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -56.16M | -97.49M | -257.44M | -110.39M | -252.97M | -73.15M | -23.38M | -40.66M | 67.99M |
| Operating CF Margin % | -31.55% | -46.93% | -76.85% | -37.46% | -119.52% | -25.01% | -12.02% | -25.38% | 28.79% |
| Operating CF Growth % | -196.98% | -73.6% | -164.06% | 57.12% | -129.16% | 71.08% | 68.03% | -73.88% | 267.23% |
| Net Income | -76.91M | -143.59M | -279.66M | -383.46M | -282.02M | -92.56M | -51.92M | -69.41M | -5.34M |
| Depreciation & Amortization | 617K | 2.42M | 38.65M | 33.59M | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Stock-Based Compensation | 8.87M | 19.04M | 11.93M | 24.46M | 0 | 17.85M | 9.32M | 7.78M | 11.28M |
| Deferred Taxes | 0 | -28.34M | -6.63M | 204.08M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.02M | 16.95M | 77.35M | 24.61M | 98.54M | -34.7M | -1.9M | 23.15M | 60.78M |
| Working Capital Changes | 7.25M | 36.02M | -99.07M | -13.67M | -105.61M | -1.44M | -20.73M | -39.68M | 0 |
| Change in Receivables | -393K | 33.38M | -22.2M | 12.01M | -24.03M | 11.7M | 994K | 4.05M | -14.14M |
| Change in Inventory | 16.79M | 26K | -29.14M | 6.16M | -24.95M | 19.79M | -2.54M | -28.4M | 2.5M |
| Change in Payables | 4.96M | 13.72M | 1.37M | 3.68M | -11.73M | 1.5M | -5.24M | -1.36M | 3.08M |
| Cash from Investing | -177.26M | 36.59M | 211.18M | -40M | 39.94M | -114K | 0 | -33K | -7.93M |
| Capital Expenditures | -1.62M | -1.61M | -6.66M | -317K | -59K | -114K | 0 | -33K | 0 |
| CapEx % of Revenue | 0.91% | 0.77% | 1.99% | 0.11% | 0.03% | 0.04% | - | 0.02% | - |
| Acquisitions | 1.62M | 6.15M | 0 | 39.69M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.62M | 32.05M | 0 | -39.69M | 0 | 0 | 0 | 0 | -7.93M |
| Cash from Financing | 116.24M | 96.56M | 88.97M | 231.72M | 133.73M | 14.6M | -25.21M | 49.66M | 72.93M |
| Debt Issued (Net) | -5K | -19K | 62.67M | 19.98M | 44.78M | -33M | -32M | 7.9M | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -426K | 0 | 0 | 0 | 0 | -1.27M | 0 |
| Other Financing | 1.31M | 647K | 560K | 1.23M | 0 | 40.07M | 1K | 385K | 72.93M |
| Net Change in Cash | -117.18M▲ 0% | 35.66M▲ 130.4% | 42.7M▲ 19.7% | 81.33M▲ 90.4% | -79.29M▼ 197.5% | -58.67M▲ 26.0% | -48.59M▲ 17.2% | 8.97M▲ 118.5% | 132.99M▲ 1382.5% |
| Free Cash Flow | -57.78M▲ 0% | -99.1M▼ 71.5% | -264.1M▼ 166.5% | -110.7M▲ 58.1% | -253.02M▼ 128.6% | -73.27M▲ 71.0% | -23.38M▲ 68.1% | -40.69M▼ 74.0% | 67.99M▲ 267.1% |
| FCF Margin % | -32.46% | -47.7% | -78.83% | -37.57% | -119.55% | -25.05% | -12.02% | -25.4% | 28.79% |
| FCF Growth % | -204.59% | -71.51% | -166.49% | 58.08% | -128.56% | 71.04% | 68.08% | -74.02% | 267.09% |
| FCF per Share | -1.33 | -0.85 | -2.23 | -0.80 | -1.52 | -0.40 | -0.12 | -0.19 | 0.26 |
| FCF Conversion (FCF/Net Income) | 0.73x | 0.57x | 0.92x | 0.29x | 0.90x | 0.78x | 0.45x | 0.59x | -12.72x |
| Interest Paid | 0 | 0 | 781K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AKBA Key Ratios
Akebia Therapeutics, Inc. (AKBA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -136.35% | -82.06% | -45.52% | -54.27% | -119.82% | -175.37% | -237.83% | - | - | -16.39% |
| Return on Invested Capital (ROIC) | - | -121.89% | -44.87% | -47.63% | -113.31% | -193.48% | -161.98% | -153.44% | -63.97% | - |
| Gross Margin | -7443% | 99.65% | 96.3% | 56.62% | 78.29% | 61.5% | 92.31% | 61.9% | 60.56% | 83.29% |
| Net Margin | -8843.45% | -43.21% | -82.75% | -83.48% | -130.61% | -133.25% | -32.22% | -26.68% | -43.33% | -2.26% |
| Debt / Equity | - | - | 0.02x | 0.27x | 0.51x | 1.84x | 19.08x | - | - | - |
| Interest Coverage | - | - | - | -204.49x | -42.59x | -13.27x | -5.15x | -7.67x | -2.78x | - |
| FCF Conversion | -0.43x | 0.73x | 0.57x | 0.92x | 0.29x | 0.90x | 0.78x | 0.45x | 0.59x | -12.72x |
| Revenue Growth | - | 11495.05% | 16.72% | 61.26% | -12.05% | -28.17% | 38.19% | -33.46% | -17.7% | 47.46% |
AKBA SEC Filings & Documents
Akebia Therapeutics, Inc. (AKBA) SEC filings — annual & quarterly reports (10-K, 10-Q)
AKBA Frequently Asked Questions
Akebia Therapeutics, Inc. (AKBA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Akebia Therapeutics, Inc. (AKBA) reported $236.2M in revenue for fiscal year 2025.
Akebia Therapeutics, Inc. (AKBA) grew revenue by 47.5% over the past year. This is strong growth.
Akebia Therapeutics, Inc. (AKBA) reported a net loss of $5.3M for fiscal year 2025.
Dividend & Returns
Akebia Therapeutics, Inc. (AKBA) has a return on equity (ROE) of -16.4%. Negative ROE indicates the company is unprofitable.
Akebia Therapeutics, Inc. (AKBA) generated $67.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More AKBA
Akebia Therapeutics, Inc. (AKBA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates